Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

Accelerated approval was based on results from the Phase Ib Beamion-LUNG 1 trial (NCT04886804), which showed a 75% objective ...

In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT. The primary end point ...

Meeting Coverage > GICS New Standard for Unresectable Hepatocellular Carcinoma? — Adding durvalumab and bevacizumab to transarterial chemoembolization almost doubles PFS by Charles Bankhead ...

The per protocol analysis included 74 patients — 36 in the liver transplant group and 38 in the chemotherapy only group. In this analysis, 5-year overall survival was 73% in the transplant group ...

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial Published Feb 19, 2024 7:05am EST ...

If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma ...